Mapping the genomic landscape of CRISPR-Cas9 cleavage

Cameron, Peter, Fuller, Chris K, Donohoue, Paul D, Jones, Brittnee N, Thompson, Matthew S, Carter, Matthew M, Gradia, Scott, Vidal, Bastien +13 more·2017·Nature Methods
DOI 10.1038/nmeth.4284

Cited by (454)

Items 101–200 of 454

  1. Protein Inhibitors of CRISPR-Cas9
    Joseph Bondy‐Denomy · 2017 · ACS Chemical Biology
  2. Molecular mechanisms, off‐target activities, and clinical potentials of genome editing systems
    Nannan Zheng, Liyang Li, Xiangdong Wang · 2020 · Clinical and Translational Medicine
  3. Systematic decomposition of sequence determinants governing CRISPR/Cas9 specificity
    Rongjie Fu, Wei He, Jinzhuang Dou, Oscar David Villarreal, Ella Bedford, Helen H. Wang, Connie Hou, Liang Zhang, Yalong Wang, Dacheng Ma et al. · 2022 · Nature Communications
  4. Computational Tools and Resources Supporting CRISPR-Cas Experiments
    Paweł Śledziński, Mateusz Nowaczyk, Marta Olejniczak · 2020 · Cells
  5. Genome-wide detection of CRISPR editing in vivo using GUIDE-tag
    Liang, Shun-Qing, Liu, Pengpeng, Smith, Jordan L., Mintzer, Esther, Maitland, Stacy, Dong, Xiaolong, Yang, Qiyuan, Lee, Jonathan, Haynes, Cole M., Zhu, Lihua Julie et al. · 2022 · Nature Communications
  6. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function
    Eliana Ruggiero, Erica Carnevale, Aaron Prodeus, Zulma Irene Magnani, Barbara Camisa, Ivan Merelli, Claudia Politano, Lorena Stasi, Alessia Potenza, Beatrice Claudia Cianciotti et al. · 2022 · Science Translational Medicine
  7. Transitioning from wet lab to artificial intelligence: a systematic review of AI predictors in CRISPR
    Ahtisham Fazeel Abbasi, Muhammad Nabeel Asim, Andreas Dengel · 2025 · Journal of Translational Medicine
  8. Genetic Renal Diseases: The Emerging Role of Zebrafish Models
    Mohamed A. Elmonem, Sante Princiero Berlingerio, Lambertus P. van den Heuvel, Peter A.M. de Witte, Martin Lowe, Elena N. Levtchenko · 2018 · Cells
  9. Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+
    Roger S. Zou, Yang Liu, Oscar E. Reyes Gaido, Maximilian F. Konig, Brian J. Mog, Leo L. Shen, Franklin J. Avilés-Vázquez, Alberto Marín-González, Taekjip Ha · 2023 · Nature Methods
  10. Baboon Envelope Pseudotyped “Nanoblades” Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+ Cells
    Alejandra Gutiérrez-Guerrero, María Jimena Abrey-Recalde, Philippe E. Mangeot, Caroline Costa, Ornéllie Bernadin, Séverine Perian, Floriane Fusil, Gisèle Froment, Adriana Martinez-Turtos, Adrien Krug et al. · 2021 · Frontiers in Genome Editing
  11. CRISPR-Cas12a exhibits metal-dependent specificity switching
    Giang T. Nguyen, Michael A. Schelling, Akshara Raju, Kathryn A. Buscher, Aneisha Sritharan, Dipali G. Sashital · 2024 · Nucleic Acids Research
  12. TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges
    E. Golikova, A. Alshevskaya, S. Alrhmoun, N. Sivitskaya, Sergey V. Sennikov · 2024 · Journal of Translational Medicine
  13. Toward Gene Transfer Nanoparticles as Therapeutics
    Erin W. Kavanagh, Jordan J. Green · 2022 · Advanced Healthcare Materials
  14. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis
    Julian David Gillmore, Ed J. Gane, Jörg Täubel, Justin Kao, Marianna Fontana, Michael L. Maitland, Jessica L. Seitzer, Daniel O'Connell, Kathryn Rose Walsh, Kristy M. Wood et al. · 2022 · Yearbook of pediatric endocrinology
  15. Effective use of sequence information to predict CRISPR-Cas9 off-target
    Zhong-Rui Zhang, Zhenran Jiang · 2022 · Computational and Structural Biotechnology Journal
  16. Combining Rapid Data Independent Acquisition and CRISPR Gene Deletion for Studying Potential Protein Functions: A Case of HMGN1
    Martin Mehnert, Wenxue Li, Chongde Wu, Barbora Šalovská, Yansheng Liu · 2019 · PROTEOMICS
  17. In vivo correction of cystic fibrosis mediated by PNA nanoparticles
    Alexandra S. Piotrowski-Daspit, Christina Barone, Chun-Yu Lin, Yanxiang Deng, Douglas H. Wu, Thomas C. Binns, Emily Xu, Adele S. Ricciardi, Rachael Putman, Alannah Garrison et al. · 2022 · Science Advances
  18. Technologies and Computational Analysis Strategies for CRISPR Applications
    Kendell Clement, Jonathan Y. Hsu, Matthew C. Canver, J. Keith Joung, Luca Pinello · 2020 · Molecular Cell
  19. Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito
    William T. Garrood, Nace Kranjc, Karl Petri, Daniel Y. Kim, Jimmy A. Guo, Andrew Hammond, Ioanna Morianou, Vikram Pattanayak, J. Keith Joung, Andrea Crisanti et al. · 2021 · Proceedings of the National Academy of Sciences
  20. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
    Ezgi Elmas, Noushin Saljoughian, Marcelo de Souza Fernandes Pereira, Brian P. Tullius, Kinnari Sorathia, Robin J. Nakkula, Dean Anthony Lee, Meisam Naeimi Kararoudi · 2022 · Frontiers in Oncology
  21. TAPE-seq is a cell-based method for predicting genome-wide off-target effects of prime editor
    Jeonghun Kwon, Minyoung Kim, Seung-Min Bae, Anna Jo, Young-Ho Kim, Jungjoon K. Lee · 2022 · Nature Communications
  22. Genome-wide detection of DNA double-strand breaks by in-suspension BLISS
    Britta A. M. Bouwman, Federico Agostini, Silvano Garnerone, Giuseppe Petrosino, Henrike Johanna Gothe, Sergi Sayols, Andreas E. Moor, Shalev Itzkovitz, Magda Bienko, Vassilis Roukos et al. · 2020 · Nature Protocols
  23. Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment Methods
    Hemangi G. Chaudhari, Jon N Penterman, Holly J. Whitton, Sarah J. Spencer, Nicole Flanagan, Maria C. Lei Zhang, Elaine Huang, Aditya S. Khedkar, J. Mike Toomey, Courtney A. Shearer et al. · 2020 · The CRISPR Journal
  24. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders
    Sudhanshu P. Raikwar, Nidhi Shankar Kikkeri, Ragha Chaitanya Sakuru, Daniyal Saeed, Haris Zahoor, Keerthivaas Premkumar, Shireen Mentor, Ramasamy Thangavel, Iuliia Dubova, Mohammad Ejaz Ahmed et al. · 2019 · Journal of Neuroimmune Pharmacology
  25. Translating CRISPR-Cas Therapeutics: Approaches and Challenges
    Lavina Sierra Tay, Nathan D. Palmer, Rebecca Panwala, Wei Leong Chew, Prashant Mali · 2020 · The CRISPR Journal
  26. CRISPECTOR provides accurate estimation of genome editing translocation and off-target activity from comparative NGS data
    Ido Amit, Ortal Iancu, Alona Levy-Jurgenson, Gavin Kurgan, Matthew McNeill, Garrett R. Rettig, Daniel G. Allen, Dor Breier, Nimrod Ben Haim, Yu Wang et al. · 2021 · Nature Communications
  27. Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34(+) hematopoietic stem and progenitor cells
    Cromer, M. Kyle, Majeti, Kiran R., Rettig, Garrett R., Murugan, Karthik, Kurgan, Gavin L., Bode, Nicole M., Hampton, Jessica P., Vakulskas, Christopher A., Behlke, Mark A., Porteus, Matthew H. · 2023 · Molecular Therapy
  28. Massively targeted evaluation of therapeutic CRISPR off-targets in cells
    Pan, Xiaoguang, Qu, Kunli, Yuan, Hao, Xiang, Xi, Anthon, Christian, Pashkova, Liubov, Liang, Xue, Han, Peng, Corsi, Giulia I., Xu, Fengping et al. · 2022 · Nature Communications
  29. Personalised genome editing – The future for corneal dystrophies
    Tara Moore, Kathleen A. Christie, John Marshall, M. Andrew Nesbit · 2018 · Progress in Retinal and Eye Research
  30. Systematic in vitro profiling of off-target affinity, cleavage and efficiency for CRISPR enzymes
    Liyang Zhang, H. Tomas Rube, Christopher A. Vakulskas, Mark A. Behlke, Harmen J. Bussemaker, Miles A. Pufall · 2020 · Nucleic Acids Research
  31. Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects
    Karl Petri, Daniel Y. Kim, Kanae E. Sasaki, Matthew C. Canver, Xiao Wang, Hina Shah, Hyunho Lee, Joy E. Horng, Kendell Clement, Sowmya Iyer et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges
    Arturo Macarrón Palacios, Patrick Korus, Bodo G. C. Wilkens, Najmeh Heshmatpour, Sarita R. Patnaik · 2024 · Frontiers in Genome Editing
  33. Enhancing Specificity, Precision, Accessibility, Flexibility, and Safety to Overcome Traditional CRISPR/Cas Editing Challenges and Shape Future Innovations
    Muna Alariqi, Mohamed Ramadan, Lu Yu, Fengjiao Hui, Amjad Hussain, Xiaofeng Zhou, Yu Yu, Xianlong Zhang, Shuangxia Jin · 2025 · Advanced Science
  34. Therapeutic genome editing in cardiovascular diseases
    Masataka Nishiga, Lei S. Qi, Joseph C. Wu · 2020 · Advanced Drug Delivery Reviews
  35. GOTI, a method to identify genome-wide off-target effects of genome editing in mouse embryos
    Erwei Zuo, Yidi Sun, Wei Wu, Tanglong Yuan, Wenqin Ying, Hao Sun, Liyun Yuan, Lars Michael Steinmetz, Yixue Li, Hui Yang · 2020 · Nature Protocols
  36. Negative DNA supercoiling induces genome-wide Cas9 off-target activity
    Matthew D. Newton, Marialucrezia Losito, Quentin M. Smith, Nishita Parnandi, Benjamin J. Taylor, Pınar Akçakaya, Marcello Maresca, Patrick van Eijk, Simon Huw Reed, Simon J. Boulton et al. · 2023 · Molecular Cell
  37. Massively parallel analysis of single-molecule dynamics on next-generation sequencing chips
    Javier Aguirre Rivera, Guanzhong Mao, Сабанцев Антон Владимирович, Mikhail Panfilov, Q. Hou, M. Lindell, Christelle Chanez, Félix Ritort, Martin Jínek, Sebastian Deindl · 2024 · Science
  38. CRISPRoffT: comprehensive database of CRISPR/Cas off-targets
    Grant Wang, Xiaona Liu, Aoqi Wang, Jianguo Wen, Pora Kim, Qianqian Song, Xiaona Liu, Xiaobo Zhou · 2024 · Nucleic Acids Research
  39. CRISPR/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells
    Daniel P. Dever, Samantha G. Scharenberg, Joab Camarena, Eric Kildebeck, Joseph T. Clark, Renata M. Martin, Rasmus Otkjær Bak, Yuming Tang, Monika Dohse, Johannes A. Birgmeier et al. · 2019 · iScience
  40. Identifying genome-wide off-target sites of CRISPR RNA–guided nucleases and deaminases with Digenome-seq
    Daesik Kim, Beum‐Chang Kang, Jin‐Soo Kim · 2021 · Nature Protocols
  41. A kinetic model predicts SpCas9 activity, improves off-target classification, and reveals the physical basis of targeting fidelity
    Behrouz Eslami-Mossallam, Misha Klein, Constantijn P. van der Smagt, Koen van der Sanden, Stephen K. Jones, John A. Hawkins, Ilya J. Finkelstein, Martin Depken · 2022 · Nature Communications
  42. Paving the way towards precise and safe CRISPR genome editing
    Paweł Śledziński, Magdalena Dabrowska, Mateusz Nowaczyk, Marta Olejniczak · 2021 · Biotechnology Advances
  43. Building CRISPR Gene Therapies for the Central Nervous System
    Sally E. Salomonsson, Claire Dudley Clelland · 2024 · JAMA Neurology
  44. Generation of a Commercial-Scale Founder Population of Porcine Reproductive and Respiratory Syndrome Virus Resistant Pigs Using CRISPR-Cas
    Brian T. Burger, Benjamin P. Beaton, Matthew A. Campbell, Benjamin Thomas Brett, Melissa S. Rohrer, Sarah Plummer, Dylan Barnes, Ke Jiang, Sudhir Naswa, Jeremy Lange et al. · 2024 · The CRISPR Journal
  45. Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells
    M. Kyle Cromer, Valentin V. Barsan, Erich B. Jaeger, Mengchi Wang, Jessica P. Hampton, Feng Chen, Drew Kennedy, Jenny Xiao, Irina Khrebtukova, Ana Granat et al. · 2022 · Nature Communications
  46. Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
    Bernice Ling Zhi Oh, Natasha Vinanica, Desmond Wong, Dario Campana · 2024 · Haematologica
  47. CRISPR-Cap: multiplexed double-stranded DNA enrichment based on the CRISPR system
    Jeewon Lee, Hyeonseob Lim, Hoon Sik Jang, Byungjin Hwang, Joon Ho Lee, Junhyuk Cho, Ji Hyun Lee, Duhee Bang · 2018 · Nucleic Acids Research
  48. Genome Editing
    Kiran Musunuru · 2017 · Journal of the American College of Cardiology
  49. crisprSQL: a novel database platform for CRISPR/Cas off-target cleavage assays
    Störtz, Florian, Minary, Peter · 2021 · Nucleic Acids Research
  50. On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes
    Alexey N. Korablev, Varvara Lukyanchikova, Irina A. Serova, Нариман Рашитович Баттулин · 2020 · International Journal of Molecular Sciences
  51. CRISPR-M: Predicting sgRNA off-target effect using a multi-view deep learning network
    Jialiang Sun, Jun Hai Guo, Jian Liu · 2024 · PLoS Computational Biology
  52. Impact of Genetic Variation on CRISPR-Cas Targeting
    Matthew C. Canver, J. Keith Joung, Luca Pinello · 2018 · The CRISPR Journal
  53. mRNA and gene editing: Late breaking therapies in liver diseases
    Nerea Zabaleta, Laura Torella, Nicholas D. Weber, Gloria González‐Aseguinolaza · 2022 · Hepatology
  54. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing
    Yu Zhang, Hui zi Li, Takahiko Nishiyama, John McAnally, Efrain Sanchez‐Ortiz, Jian Hua Huang, Pradeep P.A. Mammen, Rhonda Bassel‐Duby, Eric N. Olson · 2022 · Molecular Therapy — Nucleic Acids
  55. High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
    Émilie Degagné, Paul D. Donohoue, Suparna Roy, Jessica Scherer, Tristan W. Fowler, Ryan T. Davis, Gustavo A. Reyes, George Kwong, Morena Stanaway, Vanina Larroca Vicena et al. · 2024 · Cancer Immunology Research
  56. Strategies for High-Efficiency Mutation Using the CRISPR/Cas System
    Shuying Feng, Zilong Wang, Aifang Li, Xin Xie, Junjie Liu, Shuxuan Li, Yalan Li, Baiyan Wang, Lina Hu, Lianhe Yang et al. · 2022 · Frontiers in Cell and Developmental Biology
  57. Improved Cas9 activity by specific modifications of the tracrRNA
    Tristan A. Scott, Ryan Z. Urak, Citradewi Soemardy, Kevin V. Morris · 2019 · Scientific Reports
  58. Emerging Gene Therapeutics for Epidermolysis Bullosa under Development
    Johannes Bischof, Markus Hierl, Ulrich Koller · 2024 · International Journal of Molecular Sciences
  59. An effective vaginal gel to deliver CRISPR/Cas9 system encapsulated in poly (β-amino ester) nanoparticles for vaginal gene therapy
    Gang Niu, Zhuang Jin, Chong Zhang, Dan He, Xueqin Gao, Chenming Zou, Wei Zhang, Jiahui Ding, Bhudev Chandra Das, Konstantin Severinov et al. · 2020 · EBioMedicine
  60. Benchmarking and integrating genome-wide CRISPR off-target detection and prediction
    Jifang Yan, Dongyu Xue, Guohui Chuai, Yuli Gao, Gongchen Zhang, Qi Liu · 2020 · Nucleic Acids Research
  61. Packaged delivery of CRISPR–Cas9 ribonucleoproteins accelerates genome editing
    Hannah Karp, Madeline Zoltek, Kevin M. Wasko, Angel Luis Vazquez, Jinna I. Brim, Wayne Ngo, Alanna Schepartz, Jennifer A. Doudna · 2025 · Nucleic Acids Research
  62. The Off-Targets of Clustered Regularly Interspaced Short Palindromic Repeats Gene Editing
    Manuel M. Vicente, Miguel Chaves‐Ferreira, João M. P. Jorge, João T. Proença, Vasco M. Barreto · 2021 · Frontiers in Cell and Developmental Biology
  63. Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia
    Jesus Izaguirre-Carbonell, Luke Christiansen, Robert Burns, Jesse Schmitz, Chenxuan Li, Rebekah L. Mokry, Theresa Bluemn, Yongwei Zheng, Jian Shen, Karen-Sue Carlson et al. · 2019 · Blood Advances
  64. Illuminating the genome-wide activity of genome editors for safe and effective therapeutics
    Yong Cheng, Shengdar Q. Tsai · 2018 · Genome biology
  65. CRISPR therapy towards an HIV cure
    Elena Herrera-Carrillo, Zongliang Gao, Ben Berkhout · 2019 · Briefings in Functional Genomics
  66. DL-CRISPR: A Deep Learning Method for Off-Target Activity Prediction in CRISPR/Cas9 With Data Augmentation
    Yu Zhang, Yahui Long, Rui Yin, Chee Keong Kwoh · 2020 · IEEE Access
  67. HIV-1 cure strategies: why CRISPR?
    Andrew Atkins, Alexander G. Allen, Will Dampier, Elias K. Haddad, Michael R. Nonnemacher, Brian L. Wigdahl · 2020 · Expert Opinion on Biological Therapy
  68. AAV-mediated delivery of a Sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells
    Lupeng Ye, Stanley Z. Lam, Luojia Yang, Kazushi Suzuki, Yongji Zou, Qianqian Lin, Yueqi Zhang, Paul R. Clark, Lei Peng, Sidi Chen · 2023 · Nature Biomedical Engineering
  69. Unexpected genomic rearrangements at targeted loci associated with CRISPR/Cas9-mediated knock-in
    Amélie Rezza, Christelle Jacquet, Amélie Le Pillouer, Florian Lafarguette, Charlotte Ruptier, Marion Billandon, Patricia Isnard, Séverine Trouttet, Kader Thiam, Alexandre Fraichard et al. · 2019 · Scientific Reports
  70. Regulatory Considerations for Clinical Trial Applications with CRISPR-Based Medicinal Products
    Brigitte Anliker, Liam Harold Childs, Juliane Rau, Matthias Renner, Silke Schüle, Martina Schuessler‐Lenz, Attila Sebe · 2022 · The CRISPR Journal
  71. Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
    Minghua Xiang, Huayi Li, Yuanyuan Zhan, Ding Ma, Qinglei Gao, Yong Fang · 2024 · Molecular Cancer
  72. Linking CRISPR–Cas9 double-strand break profiles to gene editing precision with BreakTag
    Gabriel M. C. Longo, Sergi Sayols, Andriana G. Kotini, Sabine Heinen, Martin M. Möckel, Petra Beli, Vassilis Roukos · 2024 · Nature Biotechnology
  73. A versatile CRISPR/Cas9 system off-target prediction tool using language model
    Weian Du, Liang Zhao, Kaichuan Diao, Yangyang Zheng, Qianyong Yang, Zhenzhen Zhu, Xiangxing Zhu, Dongsheng Tang · 2025 · Communications Biology
  74. Tag-seq: a convenient and scalable method for genome-wide specificity assessment of CRISPR/Cas nucleases
    Hongxin Huang, Yongfei Hu, Guanjie Huang, Shufeng Ma, Jianqi Feng, Dong Wang, Ying Lin, Jiajian Zhou, Zhili Rong · 2021 · Communications Biology
  75. A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies
    Jennifer L. Dashnau, Qiong Xue, Monica Nelson, Eric Law, Lan Cao, Derek J. Hei · 2022 · Cytotherapy
  76. Engineering a New Generation of Gene Editors: Integrating Synthetic Biology and AI Innovations
    Bing Shao Chia, Samantha Seah, Bolun Wang, Kimberle Shen, Diya Srivastava, Wei Leong Chew · 2025 · ACS Synthetic Biology
  77. Genome editing in maize and sorghum: A comprehensive review of CRISPR/Cas9 and emerging technologies
    Mercy Jocyline Namata, Jingyi Xu, Ephrem Habyarimana, Sudhakar Reddy Palakolanu, Lihua Wang, Jieqin Li · 2025 · The Plant Genome
  78. The evolution and history of gene editing technologies
    Shubhchintan Randhawa, Shatakshi Sengar · 2021 · Progress in molecular biology and translational science
  79. New Frontiers: Precise Editing of Allergen Genes Using CRISPR
    Nicole F. Brackett, Anna Pomés, Martin D. Chapman · 2022 · Frontiers in Allergy
  80. CRISPR-based therapeutic genome editing for inherited blood disorders
    Sébastien Levesque, Daniel E. Bauer · 2025 · Nature Reviews Drug Discovery
  81. Genome-Wide Analysis of Off-Target CRISPR/Cas9 Activity in Single-Cell-Derived Human Hematopoietic Stem and Progenitor Cell Clones
    Richard H. Smith, Yun-Ching Chen, Fayaz Seifuddin, Daniel N. Hupalo, Camille Alba, Robert N. Reger, Xin Tian, Daisuke Araki, Clifton L. Dalgard, Richard W. Childs et al. · 2020 · Genes
  82. In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation
    Yueying Liu, Jing Yang, Zonggao Shi, Xuejuan Tan, Norman Jin, Catlin O'Brien, Connor Ott, Anna Grisoli, Eric Boya Lee, Kelly Volk et al. · 2021 · Cancer Letters
  83. Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy
    Tolulope O. Rosanwo, Daniel E. Bauer · 2021 · Molecular Therapy
  84. Progress in the application of CRISPR: From gene to base editing
    Wenyi Wu, Yanhui Yang, Hetian Lei · 2018 · Medicinal Research Reviews
  85. Engineering guide RNA to reduce the off-target effects of CRISPR
    Jing Wu, Hao Yin · 2019 · Journal of genetics and genomics/Journal of Genetics and Genomics
  86. The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption
    Zhi Qiang Yao, Madison Schank, Juan Zhao, Mohamed El Gazzar, Ling Wang, Yi Zhang, Addison C. Hill, Puja Banik, Jaeden S. Pyburn, Jonathan P. Moorman · 2024 · Frontiers in Genome Editing
  87. A positive, growth-based PAM screen identifies noncanonical motifs recognized by the S. pyogenes Cas9
    Daphne Collias, Ryan T. Leenay, Rebecca Slotkowski, Zhicheng Zuo, Scott P. Collins, B. A. McGirr, Jin Liu, Chase L. Beisel · 2020 · Science Advances
  88. CRISPR for Neuromuscular Disorders: Gene Editing and Beyond
    Courtney S. Young, April D. Pyle, Melissa J. Spencer · 2019 · Physiology
  89. PEAC-seq adopts Prime Editor to detect CRISPR off-target and DNA translocation
    Zhenxing Yu, Zhike Lu, Jingjing Li, Yingying Wang, Panfeng Wu, Yini Li, Yangfan Zhou, Bailun Li, Heng Zhang, Yingzheng Liu et al. · 2022 · Nature Communications
  90. Transformer-based anti-noise models for CRISPR-Cas9 off-target activities prediction
    Zengrui Guan, Zhenran Jiang · 2023 · Briefings in Bioinformatics
  91. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness
    Elaine K. Lau, George Kwong, Tristan W. Fowler, Bee-Chun Sun, Paul D. Donohoue, Ryan T. Davis, Mara Beth Bryan, Shannon McCawley, Starlynn Clarke, Carolyn Williams et al. · 2023 · Cytotherapy
  92. Interpretable neural architecture search and transfer learning for understanding CRISPR–Cas9 off-target enzymatic reactions
    Zijun Zhang, Adam Lamson, Michael Shelley, Olga G. Troyanskaya · 2023 · Nature Computational Science
  93. Uncovering the dynamics of precise repair at CRISPR/Cas9-induced double-strand breaks
    Daniela Ben‐Tov, Fabrizio Mafessoni, Amit Cucuy, Arik Honig, Cathy Melamed‐Bessudo, Avraham A. Levy · 2024 · Nature Communications
  94. Advances in therapeutic application of CRISPR-Cas9
    Jin‐Yu Sun, Jianchu Wang, Donghui Zheng, Xiaorong Hu · 2019 · Briefings in Functional Genomics
  95. Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine
    Xiaofeng Dai, Pilar Blancafort, Peiyu Wang, Agustin Sgro, Erik W. Thompson, Kostya Ostrikov · 2020 · Advanced Science
  96. Extru-seq: A method for predicting genome-wide Cas9 off-target sites with advantages of both cell-based and in vitro approaches
    Kwon, Jeonghun, Kim, Minyoung, Hwang, Woochang, Jo, Anna, Hwang, Gue-Ho, Jung, Minhee, Kim, Un Gi, Cui, Gang, Kim, Heonseok, Eom, Joon-Ho et al. · 2023 · Genome biology
  97. Robust CRISPR/Cas9 Genome Editing of the HUDEP-2 Erythroid Precursor Line Using Plasmids and Single-Stranded Oligonucleotide Donors
    Gemma Moir-Meyer, Pak Leng Cheong, Aude-Anaïs Olijnik, Jill M. Brown, Samantha J.L. Knight, Andrew John King, Ryo Kurita, Yukio Nakamura, Richard J. Gibbons, Douglas R. Higgs et al. · 2018 · Methods and Protocols
  98. Nonclinical safety assessment of engineered T cell therapies
    Herve N. Lebrec, Curtis C. Maier, Kazushige Maki, Rafael A. Ponce, Jacintha M. Shenton, Shon Green · 2021 · Regulatory Toxicology and Pharmacology
  99. High-Throughput Imaging of CRISPR- and Recombinant Adeno-Associated Virus–Induced DNA Damage Response in Human Hematopoietic Stem and Progenitor Cells
    Daniel G. Allen, Lucien E. Weiss, Alon Saguy, Michael Rosenberg, Ortal Iancu, Omri Matalon, Ciaran M. Lee, Katia Beider, Arnon Nagler, Yoav Shechtman et al. · 2022 · The CRISPR Journal
  100. Modelling urea cycle disorders using iPSCs
    Claire E. Duff, Julien Baruteau · 2022 · npj Regenerative Medicine